Defining treatment pathways for CLL
This month - July 2018 - the British Society of Haematology (BSH) have published their long-awaited updated guidelines on the treatment of chronic lymphocytic leukaemia (CLL).
Targeted drugs like ibrutinib, idelalisib and venetoclax have been transforming treatment for CLL over recent years and the new guidance was urgently needed to show how these drugs fit into the treatment pathway.
Research continues into how best to use these drugs and other new treatments for CLL. Find out more about the latest clinical trials for people with CLL at Lymphoma TrialsLink.